Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

March 30, 2025

Conditions
PD-1Neoadjuvant ChemoradiotherapyGastroesophageal Junction Cancer
Interventions
DRUG

PD-1inhibitor

Patients receive 3 cycles of preoperative chemotherapy with Sintilimab(PD-1 inbibitor) and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.

Trial Locations (1)

430030

RECRUITING

Min Jin, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER